Capital Influx

Financially, Forte reported a first‑quarter net loss of $1.24 per share, down from $1.37 per share a year earlier, and the acquisition will provide a significant capital influx. argenx’s global reach, development expertise, and commercial capabilities are expected to unlock FB102’s full potential and maximize its impact for patients.